| Authors: |
Pollock C; Kolling Institute, Royal North Shore Hospital, University of Sydney, 10 Westbourne St, St Leonards, Sydney, NSW, 2064, Australia. carol.pollock@sydney.edu.au., Carrero JJ; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden., Kanda E; Department of Health Data Science, Kawasaki Medical School, Kurashiki, Okayama, Japan., Ofori-Asenso R; Cardiovascular, Renal, Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Chen H; Medical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA., Garcia Sanchez JJ; Global Market Access and Pricing, AstraZeneca, Barcelona, Spain., Pentakota S; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Pecoits-Filho R; School of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil.; Arbor Research Collaborative for Health, Ann Arbor, MI, USA., Fishbane S; Division of Nephrology, Zucker School of Medicine, Great Neck, NY, USA., Lam CSP; National Heart Centre Singapore, Singapore, Singapore.; Duke National University of Singapore, Singapore, Singapore., Kashihara N; Department of Nephrology, Kawasaki Medical School, Okayama, Japan., Wheeler DC; Department of Renal Medicine, University College London, London, UK. |
